- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07946965
A Prospective External Control Arm Study in Colorectal Cancer (COLOSSAL)
NPM-009/COLOSSAL: A Prospective, Always-On Study to Generate Standardized External Control Arms Across Metastatic and MRD-Positive Early-Stage Colorectal Cancer
The goal of this observational, external control arm study is to make clinical trials faster, speed up developments of new therapies, and make trials more accessible to patients being treated at community oncology clinics.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The purpose of this research is to better understand what treatments are given to patients with colorectal cancer, how the disease responds to treatments, and the generate reliable data that can be used as a comparison for new drugs in development.
Studietyp
Inskrivning (Beräknad)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients with early stage or metastatic colorectal cancer
Beskrivning
Global Inclusion Criteria:
- 18 years at the time of initial colorectal cancer diagnosis
- Able to understand and provide informed consent
- Pathologically confirmed colorectal cancer per College of American Pathologists (CAP) guidelines
- Evidence of biomarker testing on tissue and/or blood
Early Stage CRC Inclusion Criteria
- Stage II-III disease per AJCC
- Positive ctDNA MRD results for specimen collected 4-8 weeks after curative intent surgery and before any adjuvant therapy
- Planning to start adjuvant therapy, or started it within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1, documented on or within 21 days before the start of adjuvant therapy
- CT of the chest, abdomen, and pelvis (CT CAP) with contrast performed after surgery and up to 6 weeks prior to the start of adjuvant therapy
Metastatic CRC Inclusion Criteria
- Stage IV disease per AJCC or metastatic recurrence
- Planning to start adjuvant therapy, or started within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1 documented on or within 21 days before the start of the new line of therapy
- CT of the chest, abdomen, and pelvis (CT-CAP) with contrast performed after surgery and up to 6 weeks prior to the start of a new line of therapy
Exclusion Criteria:
- Current enrollment in an interventional clinical trial
- Active therapy for a second, unrelated malignancy (excluding hormonal adjuvant therapy for breast cancer)
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Early Stage MRD positive
|
|
Metastatic disease
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsram: 5 years
|
Time from index date to the first evidence of progression assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on protocol imaging, or death, whichever occurs first. bicrPFS (months)=[(earliest date of BICR progression, death, or censoring-index date) +1] / 30.4375 |
5 years
|
|
Overall Response Rate (ORR)
Tidsram: 5 years
|
Proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) during a given line of therapy, from index until progression or the start of the next line, whichever occurs first, assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on-protocol imaging. Ranked CR ≥ PR ≥ stable disease (SD) ≥ progressive disease (PD) ≥ not evaluable (NE). CR and PR are confirmed by a subsequent assessment at least 28 days later. When the minimum interval is not met, BOR is determined by subsequent assessments. Participants lost to follow-up after an SD assessment that does not meet the minimum interval have a BOR of NE. bicrORR (%) = (number of participants with BOR of CR or PR from index until earliest date of BICR progression or next line start ÷ number of participants in the response population) × 100 |
5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to Next Treatment (TTNT)
Tidsram: 5 years
|
Time from index to the start of the next line of therapy or death, whichever occurs first. Participants who do not initiate a next line of therapy are censored at earliest of loss to followup and data cutoff. TTNT (months) = [(earliest date of next line start, death, or censoring - index date) + 1] ÷ 30.4375. |
5 years
|
|
Overall Survival (OS)
Tidsram: 5 years
|
Time from index to death from any cause. A missing date of death indicates the participant is alive at data cutoff, and the participant is censored at data cutoff. OS (months) = [(earliest date of death or censoring - index date) + 1] ÷ 30.4375 |
5 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NPM-009
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .